These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24284318)

  • 1. Antigenic properties of the HIV envelope on virions in solution.
    Ray K; Mengistu M; Yu L; Lewis GK; Lakowicz JR; DeVico AL
    J Virol; 2014 Feb; 88(3):1795-808. PubMed ID: 24284318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.
    Ray K; Mengistu M; Orlandi C; Pazgier M; Lewis GK; DeVico AL
    Front Immunol; 2019; 10():1512. PubMed ID: 31338095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells.
    Mengistu M; Ray K; Lewis GK; DeVico AL
    PLoS Pathog; 2015 Mar; 11(3):e1004772. PubMed ID: 25807494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.
    Mengistu M; Tang AH; Foulke JS; Blanpied TA; Gonzalez MW; Spouge JL; Gallo RC; Lewis GK; DeVico AL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E9893-E9902. PubMed ID: 29087304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.
    Lai RP; Yan J; Heeney J; McClure MO; Göttlinger H; Luban J; Pizzato M
    PLoS Pathog; 2011 Dec; 7(12):e1002442. PubMed ID: 22194689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
    J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail.
    Durham ND; Yewdall AW; Chen P; Lee R; Zony C; Robinson JE; Chen BK
    J Virol; 2012 Jul; 86(14):7484-95. PubMed ID: 22553332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
    Finnegan CM; Berg W; Lewis GK; DeVico AL
    J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    Rao PG; Lambert GS; Upadhyay C
    J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
    Yuan W; Bazick J; Sodroski J
    J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
    Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
    Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.
    Poignard P; Moulard M; Golez E; Vivona V; Franti M; Venturini S; Wang M; Parren PW; Burton DR
    J Virol; 2003 Jan; 77(1):353-65. PubMed ID: 12477840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.